Sign Up
OverviewAPI
A securities class action lawsuit has been filed against Assertio Holdings, Inc. for alleged violations of federal securities laws due to misleading statements resulting in investor losses. The FDA approval for a generic version of Assertio's product by Zydus Lifesciences Limited led to a decline in stock price and a withdrawal of financial outlook, prompting investors to join the class action before March 5, 2024.

Ask a question